Healthcare provider profile · identity verified

Andrew E Lan, MD

Internal Medicine · YONKERS, NY · NPI 1003856964

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	885	317
Atorvastatin Calcium	Atorvastatin Calcium	657	268
Losartan Potassium	Losartan Potassium	457	172
Hydrochlorothiazide	Hydrochlorothiazide	452	162
Metoprolol Succinate	Metoprolol Succinate	395	138
Metformin Hcl	Metformin Hcl	394	142
Lisinopril	Lisinopril	354	127
Simvastatin	Simvastatin	323	121
Levothyroxine Sodium	Levothyroxine Sodium	239	75
Rosuvastatin Calcium	Rosuvastatin Calcium	183	66
Nifedipine Er	Nifedipine	175	65
Albuterol Sulfate Hfa	Albuterol Sulfate	149	54
Omeprazole	Omeprazole	149	62
Gabapentin	Gabapentin	138	53
Eliquis	Apixaban	132	41
Tamsulosin Hcl	Tamsulosin Hcl	118	44
Metformin Hcl Er	Metformin Hcl	112	45
Fluticasone Propionate	Fluticasone Propionate	94	38
Pantoprazole Sodium	Pantoprazole Sodium	89	31
Furosemide	Furosemide	88	42
Metoprolol Tartrate	Metoprolol Tartrate	87	29
Ozempic	Semaglutide	87	24
Ezetimibe	Ezetimibe	85	31
Pravastatin Sodium	Pravastatin Sodium	83	31
Trazodone Hcl	Trazodone Hcl	82	20
Glimepiride	Glimepiride	76	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	74	24
Januvia	Sitagliptin Phosphate	65	24
Famotidine	Famotidine	64	23
Ibuprofen	Ibuprofen	61	22
Chlorthalidone	Chlorthalidone	59	20
Atenolol	Atenolol	58	20
Carvedilol	Carvedilol	58	26
Montelukast Sodium	Montelukast Sodium	58	18
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	56	18
Glipizide	Glipizide	56	21
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	50	17
Trulicity	Dulaglutide	49	12
Hydralazine Hcl	Hydralazine Hcl	48	21
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	48	20
Finasteride	Finasteride	47	16
Clopidogrel	Clopidogrel Bisulfate	46	20
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	46	15
Zolpidem Tartrate	Zolpidem Tartrate	46	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	45	14
Jardiance	Empagliflozin	44	16
Allopurinol	Allopurinol	41	18
Sertraline Hcl	Sertraline Hcl	40	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	38	suppressed
Pregabalin	Pregabalin	37	suppressed
Alendronate Sodium	Alendronate Sodium	35	13
Warfarin Sodium	Warfarin Sodium	35	suppressed
Naproxen	Naproxen	34	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	15
Meclizine Hcl	Meclizine Hcl	32	19
Meloxicam	Meloxicam	32	suppressed
Tramadol Hcl	Tramadol Hcl	32	18
Valsartan	Valsartan	32	11
Farxiga	Dapagliflozin Propanediol	30	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	30	11
Irbesartan	Irbesartan	28	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	28	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	27	11
Enalapril Maleate	Enalapril Maleate	27	suppressed
Jantoven	Warfarin Sodium	26	suppressed
Synthroid	Levothyroxine Sodium	26	suppressed
Xarelto	Rivaroxaban	26	suppressed
Single Use Swab	Alcohol Antiseptic Pads	25	15
Verapamil Er	Verapamil Hcl	25	suppressed
Glipizide Er	Glipizide	24	12
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Arnuity Ellipta	Fluticasone Furoate	21	suppressed
Methocarbamol	Methocarbamol	21	suppressed
Ramipril	Ramipril	21	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	20	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	19	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	19	suppressed
Baclofen	Baclofen	18	suppressed
Ketoconazole	Ketoconazole	18	suppressed
Novolog Flexpen	Insulin Aspart	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Torsemide	Torsemide	17	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	16	suppressed
Colchicine	Colchicine	16	suppressed
Prednisone	Prednisone	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Alprazolam	Alprazolam	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Vascepa	Icosapent Ethyl	13	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	12	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	12	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error